Skip to main content

Keros Therapeutics, Inc.

KROS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001664710

In the last 90 days, Keros Therapeutics, Inc. insiders filed 2 open-market purchases and 4 sales; 132 institutions reported holding it in 13F filings for Q2 2026, worth $198.6M in total; no superinvestor holds it.

13F holders, Q1 2022

Institutional positions in Keros Therapeutics, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
106
+7 vs. Q4 2021
Shares held
16.4M
+269.1K (+1.7%) vs. Q4 2021
Total value
$893.0M
−$51.5M (−5.5%) vs. Q4 2021
New holders
14
38 more added
Sold out
7
24 more reduced

Compare with Q4 2021: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting KROS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ1 2022: 106 institutions
Q1 2021: 83 institutionsQ2 2021: 80 institutionsQ3 2021: 89 institutionsQ4 2021: 99 institutionsQ1 2022: 106 institutionsQ2 2022: 104 institutionsQ3 2022: 113 institutionsQ4 2022: 126 institutionsQ1 2023: 129 institutionsQ2 2023: 123 institutionsQ3 2023: 107 institutionsQ4 2023: 121 institutionsQ1 2024: 147 institutionsQ2 2024: 152 institutionsQ3 2024: 164 institutionsQ4 2024: 161 institutionsQ1 2025: 156 institutionsQ2 2025: 139 institutionsQ3 2025: 155 institutionsQ4 2025: 166 institutionsQ1 2026: 151 institutionsQ2 2026: 132 institutions
Value heldQ1 2022: $893.0M
Q1 2021: $887.0MQ2 2021: $599.7MQ3 2021: $545.4MQ4 2021: $944.5MQ1 2022: $893.0MQ2 2022: $479.7MQ3 2022: $680.1MQ4 2022: $948.2MQ1 2023: $937.0MQ2 2023: $901.0MQ3 2023: $730.6MQ4 2023: $1.02BQ1 2024: $2.08BQ2 2024: $1.44BQ3 2024: $2.03BQ4 2024: $582.1MQ1 2025: $428.6MQ2 2025: $479.6MQ3 2025: $558.0MQ4 2025: $408.4MQ1 2026: $205.6MQ2 2026: $198.6M
Institutions holding KROS and their total value by quarter
QuarterHoldersValue
Q2 2026132$198.6M
Q1 2026151$205.6M
Q4 2025166$408.4M
Q3 2025155$558.0M
Q2 2025139$479.6M
Q1 2025156$428.6M
Q4 2024161$582.1M
Q3 2024164$2.03B
Q2 2024152$1.44B
Q1 2024147$2.08B
Q4 2023121$1.02B
Q3 2023107$730.6M
Q2 2023123$901.0M
Q1 2023129$937.0M
Q4 2022126$948.2M
Q3 2022113$680.1M
Q2 2022104$479.7M
Q1 2022106$893.0M
Q4 202199$944.5M
Q3 202189$545.4M
Q2 202180$599.7M
Q1 202183$887.0M

Institutions, Q1 2022

Shares, value and share of portfolio for each institution holding Keros Therapeutics, Inc.; share changes are against Q4 2021.

Institutions holding KROS in Q1 2022
InstitutionSharesValue% of portfolioChange in sharesAction
Nantahala Capital Management, LLC816,830$44.4M3.07%+20,132+2.5%Added
Alkeon Capital Management LLC906,433$49.3M0.22%−20,000−2.2%Reduced
BlackRock Inc.1,298,046$70.6M0.00%+11,520+0.9%Added
Deep Track Capital, LP1,380,306$75.1M4.85%+80,306+6.2%Added
OrbiMed Advisors LLC1,679,417$91.3M1.48%00.0%Unchanged
FMR LLC3,007,936$163.6M0.01%−496,862−14.2%Reduced
Darwin Global Management, Ltd.0$00.00%−111,500−100.0%Sold out
Point72 Asset Management, L.P.0$00.00%−63,028−100.0%Sold out
Parametric Portfolio Associates LLC0$00.00%−3,981−100.0%Sold out
Arizona State Retirement System0$00.00%−3,455−100.0%Sold out
Cubist Systematic Strategies, LLC0$00.00%−214−100.0%Sold out
Point72 Hong Kong Ltd0$00.00%−198−100.0%Sold out
Quantbot Technologies LP0$00.00%−200−100.0%Sold out